芜菁酸性多糖体内抗肿瘤活性研究  

The antitumor activity of Brassica rapa L.acid polysaccharides in vivo

作　　者：古丽米拉·卡德尔 阿曼妮萨·麦提如则 李明珠 康金森[1] 海力茜·陶尔大洪[1,2,3] KADEER Gulimila;MAITIRUZE Amannisa;LI Mingzhu;KANG Jinsen;TAOERDAHONG Hailiqian(School of Pharmacy,Xinjiang Medical University,Urumqi,Xinjiang 830011,China;Engineering Research Center of Xinjiang and Central Asian Medicine Resources,Ministry of Education,Urumqi,Xinjiang 830011,China;Xinjiang Key Laboratory of Natural Drug Active Fraction and Drug Release Technology,Urumqi,Xinjiang 830011,China)

机构地区：[1]新疆医科大学药学院,新疆乌鲁木齐830011 [2]新疆及中亚特色医药资源教育部工程研究中心,新疆乌鲁木齐830011 [3]新疆天然药物活性组分与释药技术重点实验室,新疆乌鲁木齐830011

出　　处：《食品与机械》2024年第3期149-155,共7页Food and Machinery

基　　金：国家自然科学基金(编号:81960765);新疆维吾尔自治区重大科技专项项目(编号:2022A03007-3);新疆天然药物活性组分与释药技术重点实验室项目(编号:XJDX1713)。

摘　　要：目的:探究芜菁酸性多糖一组分(BRAP-1)对非小细胞肺癌H226细胞荷瘤小鼠的影响。方法:将60只小鼠分为模型组(0.1 mL/10 g)、阳性药物顺铂组[3 mg/(kg·2 d)]、BRAP-1低剂量组[50 mg/(kg·d)]、BRAP-1中剂量组[100 mg/(kg·d)]和BRAP-1高剂量组[200 mg/(kg·d)]。试验期间观察小鼠肿瘤生长情况,计算抑瘤率、脏器指数;酶联免疫法检测各组小鼠血清中的白细胞介素18(IL-18)、IL-1β和肿瘤坏死因子α(TNF-α)含量;实时荧光定量核酸扩增法(q-PCR)、免疫印迹试验检测IL-18、IL-1β、受体相互作用蛋白1(RIP-1)、RIP3、混合谱系激酶结构域样蛋白(MLKL)基因表达情况。结果:与模型组相比较,BRAP-1低、中剂量组抑瘤效果明显(P<0.05),阳性组和BRAP-1高剂量组抑瘤率效果显著(P<0.01);模型组与其他各组相比较,阳性组和BRAP-1高剂量组小鼠血清中IL-1β含量显著增加(P<0.01),IL-18、TNF-ɑ在阳性组中明显降低(P<0.05),BRAP-1各剂量组中显著增加(P<0.01);q-PCR、免疫印迹试验结果显示,与模型组相比IL-1β随给药剂量增加mRNA相对表达量减少(P<0.01),而IL-18、MLKL、RIP1、RIP3的mRNA及蛋白相对表达量增加(P<0.01)。结论:BRAP-1可以通过调节免疫细胞因子水平,上调坏死性凋亡相关蛋白MLKL、RIP1、RIP3抑制肺鳞癌H226细胞体内生长。Objective:To explore the effects of Brassica rapa L.acid polysaccharide 1(BRAP-1)on H226 cell tumor-bearing mice.Methods:60 mice were divided into the model group(0.1 mL/10 g),positive cisplatin[3 mg/(kg·2 d)],BRAP-1 low dose[50 mg/(kg·d)],BRAP-1 medium dose[100 mg/(kg·d)]and BRAP-1 high dose[200 mg/(kg·d)].During the experiment,the tumor growth of mice was observed,and the tumor inhibition rate and organ index were calculated;The levels of interleukin-18(IL-18),interleukin-1β(IL-1β)and tumor necrosis factor-α(TNF-α)in serum were detected by enzyme-linked immunosorbent assay.The gene expressions of IL-18,IL-1β,RIP-1(receptor-interacting protein-1),RIP3 and MLKL(mixed-lineage kinase domain-like protein 3)were detected by Real-time Quantitative PCR(q-PCR)and Western blot(WB).Results:Compared with the model group,the low and middle dose of BRAP-1 groups had significant tumor inhibition effects(P<0.05),and the positive group and the high dose of BRAP-1 group had significant tumor inhibition effects(P<0.01).Compared with other groups in the model group,the serum levels of IL-1βin the positive group and the high dose of BRAP-1 group were significantly increased(P<0.01),IL-18 and TNF-αwere significantly decreased in the positive group(P<0.05),and were significantly increased in each dose of BRAP-1 group(P<0.01).The results of q-PCR and Western blot showed that compared with the model group,the relative expression of IL-1βmRNA decreased with the increase of BRAP-1 dose(P<0.01),while the relative expression of IL-18,MLKL,RIP1,and RIP3 mRNA and protein increased(P<0.01).Conclusion:BRAP-1 can inhibit the growth of lung squamous carcinoma H226 cells by regulating the necrotizing apoptosis-related proteins MLKL,RIP1,and RIP3 and regulating immune cytokine levels.

关 键 词：芜菁 多糖 非小细胞肺癌 H226细胞 荷瘤小鼠 

分 类 号：TS201.4[轻工技术与工程—食品科学] R285.5[轻工技术与工程—食品科学与工程]